IDEAYA BIOSCIENCES INC (IDYA)
Health Care · Precision oncology and biomarker-driven drug development · NASDAQ
IDEAYA is a precision oncology company leveraging tumor genetics and DNA damage response pathways to develop targeted cancer therapies, with multiple clinical-stage candidates supported by collaborations with major pharma partners.
What IDEAYA BIOSCIENCES INC does
IDEAYA Biosciences is a precision oncology company developing targeted cancer therapies with a focus on synthetic lethal and DNA damage response pathways. The company combines its tumor genetic information platform with clinical-stage drug candidates to address various cancers through mechanism-driven precision medicine approaches. IDEAYA's pipeline includes multiple drug candidates in Phase 1/2 and Phase 2/3 clinical trials, supported by strategic collaborations with major biopharmaceutical partners like Gilead Sciences and Pfizer.
Themes: ["Precision oncology","Synthetic lethal cancer therapies","DNA damage response pathways","Biomarker-driven drug development","Phase-stage clinical oncology"]
Fundamentals
- Price$37.28 as of 2026-07-09 close
- Market cap$3.6B as of 2026-07-10
- 1-year return+62.3% as of 2026-07-09 close
- Net margin-27.8% as of 2026-07-10
- ROE-13.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+3118.1% as of 2026-07-10
- Revenue CAGR (3y)+62.5% SEC XBRL
- Beta-0.10 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: multiple product candidates in early-stage trials with uncertain efficacy and safety outcomes, particularly darovasertib in Phase 2/3 trials","Regulatory and commercialization risk: dependency on obtaining FDA approvals, maintaining companion diagnostic availability, and achieving adoption of precision medicine approach in oncology","Cash burn and funding risk: company is unprofitable with significant R&D expenses ($95.7M in Q1 2026) and limited collaboration revenue, requiring sustained capital access to complete clinical programs"]
Competitors & peers
- Gritstone bio
- Tempus AI
- Foundation Medicine (acquired by Roche)
- Guardant Health
- NeoGenomics
- Exact Sciences
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.